October means it’s Breast Cancer Awareness Month! Early detection for any type of cancer is essential to patient health. Treatment is more likely to be successful and less intrusive, the sooner detection occurs.  Breast cancer is no exception. According to the American Cancer Society, the death rate among women with breast cancer decreased by 40% from 1989 to 2017.  This decrease is attributed to improvements in early intervention. Although some women don’t experience any symptoms at all, it is still suggested that at-risk patients get annual breast imaging, some of which may result in the need for a biopsy.

There are many tools available to study biopsies.  Molecular testing is one of the tools providing insights into the early diagnosis, prognosis, therapeutic targeting, and monitoring of cancer.  LaunchWorks CDMO partners with companies to develop and optimize cancer diagnostic products for commercial, large-scale manufacturing. LaunchWorks provides an expansive list of services, from creating custom pilot lot kits for high complexity products to fully commercialized kitting and fulfillment.  

LaunchWorks is proud to support those in the fight against breast cancer and honor those that have lost the battle. For more information about how LaunchWorks supports early breast cancer detection, contact us here. 


LaunchWorks is:  

    • FDA Registered 
    • ISO 13485:2016 Certified 
    • cGMP Compliant 
    • Full-Service from Development to Commercialization 
    • Contract manufacturer